

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Respectfully submitted,



---

Anthony J. Zelano, Reg. No. 27,969  
Attorney for Applicants  
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Boulevard, Suite 1400  
Arlington, VA 22201  
Direct Dial: 703-812-5311  
Facsimile: 703-243-6410  
Email: zelano@mwzb.com

AJZ:jmm

09830288-042501  
T05240-88200860

VERSION WITH MARKINGS TO SHOW CHANGES MADE

A new paragraph was inserted in the specification. Therefore a marked up version is not required.

Claim 3, 5, 7-11 have been amended as follows:

3. (Amended) Composition according to ~~one of claims~~ claim 1 ~~or 2~~, characterized in that component B consists of one or more compounds selected from dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, 5,10-methenyltetrahydrofolic acid or their physiologically acceptable salts.

5. (Amended) Composition according to ~~one of claims~~ claim 1 ~~to 4~~, characterized in that component C consists of one or more compounds selected from mono-, di- or triglycoside bioflavonoids containing the aglycone quercetin.

7. (Amended) Composition according to ~~one of claims~~ claim 1 ~~to 6~~ for the treatment and prevention of transmethylation disorders.

8. (Amended) Composition according to ~~one of claims~~ claim 1 ~~to 6~~ for the treatment and prevention of cardiovascular diseases.

9. (Amended) Composition according to ~~one of claims~~ claim 1 ~~to 6~~ for the treatment and prevention of atherogenic and/or thrombogenic diseases.

10. (Amended) Composition according to ~~one of claims~~ claim 1 ~~to 6~~ for the treatment and prevention of diseases associated with hyperhomocysteinemia.

11. (Amended) Composition according to ~~one of claims~~ claim 1 ~~to 6~~ for the treatment and prevention of premature occlusive arterial disease, severe vascular disease in infancy and childhood, progressive arterial stenosis, intermittent claudication, renovascular hypertension, ischemic cerebrovascular disease, premature retinal artery and retinal vein occlusion, cerebral occlusive arterial disease, occlusive peripheral arterial disease, premature death due to thromboembolic disease and/or ischemic heart disease.

09830288 042501